0000000000985792

AUTHOR

G. R. Rizzo

showing 1 related works from this author

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

2022

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinua…

Antiseizure medicationFocal seizuresAntiseizure medication; Brivaracetam; Epilepsy; Focal seizures.Antiseizure medication; Brivaracetam; Epilepsy; Focal seizures;EpilepsyNeurologyBrivaracetamSettore MED/26 - NeurologiaNeurology (clinical)Antiseizure medication; Brivaracetam; Epilepsy; Focal seizuresSettore MED/26Settore MED/39 - Neuropsichiatria Infantile
researchProduct